Merck KGaA snaps up German CDMO in boost to mRNA portfolio — including for Covid-19
Once thought unlikely as a mechanism of action in vaccines, mRNA-based shots have stormed out to a lead in the fight against Covid-19. But mRNA’s potential effect isn’t limited to just vaccines, and now German drugmaker Merck KGaA is looking to find out just how far it can take the technology.
The Darmstadt, Germany based biopharma has acquired mRNA CDMO AmpTec in Hamburg, saying it plans to strengthen its own capacities to develop and manufacture mRNA for customers to use in “vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.